POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis

Pigment Cell and Melanoma Research

Volumn 21, Issue 6, 2008, Pages 611-626

  Cook, Anthony L ^a   Sturm, Richard A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

BRN2; Differentiation; Melanocyte; Melanoma; MITF; POU

Indexed keywords

MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR POU;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL TRANSFORMATION; ENZYME ACTIVATION; GENE CONTROL; HUMAN; MELANOCYTE; MELANOMA; PHENOTYPE; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW;

GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MELANOCYTES; MELANOMA; POU DOMAIN FACTORS;

MAMMALIA;

EID: 56249083567     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2008.00510.x     Document Type: Review

References (163)

1. Abate-Shen, C. (2003). Homeobox genes and cancer: new OCTaves for an old tune. Cancer Cell 4, 329 330.
2. Ahmad, I., Hoessli, D.C., Walker-Nasir, E., Rafik, S.M., Shakoori, A.R. Nasir Ud, D. (2006). Oct-2 DNA binding transcription factor: functional consequences of phosphorylation and glycosylation. Nucleic Acids Res. 34, 175 184.
3. Alazard, R., Blaud, M., Elbaz, S., Vossen, C., Icre, G., Joseph, G., Nieto, L. Erard, M. (2005). Identification of the 'NORE' (N-Oct-3 responsive element), a novel structural motif and composite element. Nucleic Acids Res. 33, 1513 1523.
4. Alazard, R., Mourey, L., Ebel, C., Konarev, P.V., Petoukhov, M.V., Svergun, D.I. Erard, M. (2007). Fine-tuning of intrinsic N-Oct-3 POU domain allostery by regulatory DNA targets. Nucleic Acids Res. 35, 4420 4432.
5. Ambrosetti, D.C., Basilico, C. Dailey, L. (1997). Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. Mol. Cell. Biol. 17, 6321 6329.
6. Atanasoski, S., Schreiber, E., Fontana, A. Herr, W. (1997). N-Oct 5 is generated by in vitro proteolysis of the neural POU-domain protein N-Oct 3. Oncogene 14, 1287 1294.
7. Augustijn, K.D., Duval, D.L., Wechselberger, R., Kaptein, R., Gutierrez-Hartmann, A. Van Der Vliet, P.C. (2002). Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphorylation regulates PIT-1/ETS-1 binding. Proc. Natl Acad. Sci. USA 99, 12657 12662.
8. Bailey, P.J., Klos, J.M., Andersson, E., Karlen, M., Kallstrom, M., Ponjavic, J., Muhr, J., Lenhard, B., Sandelin, A. Ericson, J. (2006). A global genomic transcriptional code associated with CNS-expressed genes. Exp. Cell Res. 312, 3108 3119.
9. Baranek, C., Sock, E. Wegner, M. (2005). The POU protein Oct-6 is a nucleocytoplasmic shuttling protein. Nucleic Acids Res. 33, 6277 6286.
10. Baxter, L.L., Hsu, B.J., Umayam, L., Wolfsberg, T.G., Larson, D.M., Frith, M.C., Kawai, J., Hayashizaki, Y., Carninci, P. Pavan, W.J. (2007). Informatic and genomic analysis of melanocyte cDNA libraries as a resource for the study of melanocyte development and function. Pigment Cell Res. 20, 201 209.
11. Bennett, D.C. Lamoreux, M.L. (2003). The color loci of mice - a genetic century. Pigment Cell Res. 16, 333 344.
12. Berking, C., Takemoto, R., Satyamoorthy, K., Shirakawa, T., Eskandarpour, M., Hansson, J., Vanbelle, P.A., Elder, D.E. Herlyn, M. (2004). Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res. 64, 807 811.
13. Blaud, M., Vossen, C., Joseph, G., Alazard, R., Erard, M. Nieto, L. (2004). Characteristic patterns of N Oct-3 binding to a set of neuronal promoters. J. Mol. Biol. 339, 1049 1058.
14. Bondurand, N., Pingault, V., Goerich, D.E., Lemort, N., Sock, E., Caignec, C.L., Wegner, M. Goossens, M. (2000). Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum. Mol. Genet. 9, 1907 1917.
15. Botquin, V., Hess, H., Fuhrmann, G., Anastassiadis, C., Gross, M.K., Vriend, G. Scholer, H.R. (1998). New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2. Genes Dev. 12, 2073 2090.
16. Boulon, S., Dantonel, J.C., Binet, V., Vie, A., Blanchard, J.M., Hipskind, R.A. Philips, A. (2002). Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism. Mol. Cell. Biol. 22, 7769 7779.
17. Boyer, L.A., Lee, T.I., Cole, M.F. et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947 956.
18. Caelles, C., Hennemann, H. Karin, M. (1995). M-phase-specific phosphorylation of the POU transcription factor GHF-1 by a cell cycle-regulated protein kinase inhibits DNA binding. Mol. Cell. Biol. 15, 6694 6701.
19. Carreira, S., Goodall, J., Aksan, I., La Rocca, S.A., Galibert, M.D., Denat, L., Larue, L. Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764 769.
20. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L. Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426 3439.
21. Castro, D.S., Skowronska-Krawczyk, D., Armant, O. et al. (2006). Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. Dev. Cell. 11, 831 844.
22. Cepek, K.L., Chasman, D.I. Sharp, P.A. (1996). Sequence-specific DNA binding of the B-cell-specific coactivator OCA-B. Genes Dev. 10, 2079 2088.
23. Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S. Smith, A. (2003). Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113, 643 655.
24. Chasman, D., Cepek, K., Sharp, P.A. Pabo, C.O. (1999). Crystal structure of an OCA-B peptide bound to an Oct-1 POU domain/octamer DNA complex: specific recognition of a protein-DNA interface. Genes Dev. 13, 2650 2657.
25. Chen, R.P., Ingraham, H.A., Treacy, M.N., Albert, V.R., Wilson, L. Rosenfeld, M.G. (1990). Autoregulation of pit-1 gene expression mediated by two cis-active promoter elements. Nature 346, 583 586.
26. Cheung, M. Briscoe, J. (2003). Neural crest development is regulated by the transcription factor Sox9. Development 130, 5681 5693.
27. Chew, J.L., Loh, Y.H., Zhang, W. et al. (2005). Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol. Cell. Biol. 25, 6031 6046.
28. Christensen, C. Guldberg, P. (2005). Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF. Oncogene 24, 6292 6302.
29. Cobrinik, D., Francis, R.O., Abramson, D.H. Lee, T.C. (2006). Rb induces a proliferative arrest and curtails Brn-2 expression in retinoblastoma cells. Mol. Cancer 5, 72.
30. Collin, R.W., Chellappa, R., Pauw, R.J. et al. (2008). Missense mutations in POU4F3 cause autosomal dominant hearing impairment DFNA15 and affect subcellular localization and DNA binding. Hum. Mutat. 29, 545 554.
31. Cook, A.L., Donatien, P.D., Smith, A.G., Murphy, M., Jones, M.K., Herlyn, M., Bennett, D.C., Leonard, J.H. Sturm, R.A. (2003). Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J. Invest. Dermatol. 121, 1150 1159.
32. Cook, A.L., Smith, A.G., Smit, D.J., Leonard, J.H. Sturm, R.A. (2005). Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. Exp. Cell Res. 308, 222 235.
33. Cox, P.M., Temperley, S.M., Kumar, H. Goding, C.R. (1988). A distinct octamer-binding protein present in malignant melanoma cells. Nucleic Acids Res. 16, 11047 11056.
34. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949 954.
35. De Kok, Y.J., Cremers, C.W., Ropers, H.H. Cremers, F.P. (1997). The molecular basis of X-linked deafness type 3 (DFN3) in two sporadic cases: identification of a somatic mosaicism for a POU3F4 missense mutation. Hum. Mutat. 10, 207 211.
36. Di Rocco, G., Gavalas, A., Popperl, H., Krumlauf, R., Mavilio, F. Zappavigna, V. (2001). The recruitment of SOX/OCT complexes and the differential activity of HOXA1 and HOXB1 modulate the Hoxb1 auto-regulatory enhancer function. J. Biol. Chem. 276, 20506 20515.
37. Dugast, C. Weber, M.J. (2001). NF-Y binding is required for transactivation of neuronal aromatic L- amino acid decarboxylase gene promoter by the POU-domain protein Brn-2. Brain Res. Mol. Brain Res. 89, 58 70.
38. Eisen, T.G. (1996). The control of gene expression in melanocytes and melanomas. Melanoma Res. 6, 277 284.
39. Eisen, T., Easty, D.J., Bennett, D.C. Goding, C.R. (1995). The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11, 2157 2164.
40. Flammiger, A., Besch, R., Cook, A.L., Maier, T., Sturm, R.A. Berking, C. (2008). SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells. J. Invest. Dermatol. doi :.
41. Friedrich, R.P., Schlierf, B., Tamm, E.R., Bosl, M.R. Wegner, M. (2005). The class III POU domain protein Brn-1 can fully replace the related Oct-6 during schwann cell development and myelination. Mol. Cell. Biol. 25, 1821 1829.
42. Ghislain, J. Charnay, P. (2006). Control of myelination in Schwann cells: a Krox20 cis-regulatory element integrates Oct6, Brn2 and Sox10 activities. EMBO Rep. 7, 52 58.
43. Gidekel, S., Pizov, G., Bergman, Y. Pikarsky, E. (2003). Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4, 361 370.
44. Goodall, J., Martinozzi, S., Dexter, T.J., Champeval, D., Carreira, S., Larue, L. Goding, C.R. (2004a). Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol. Cell. Biol. 24, 2915 2922.
45. Goodall, J., Wellbrock, C., Dexter, T.J., Roberts, K., Marais, R. Goding, C.R. (2004b). The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24, 2923 2931.
46. Goodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo, P., Sturm, R., Larue, L. Goding, C.R. (2008). Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res. 68, 7788 7794.
47. Grenfell, S.J., Latchman, D.S. Thomas, N.S. (1996). Oct-1 [corrected] and Oct-2 DNA-binding site specificity is regulated in vitro by different kinases. Biochem. J. 315, 889 893.
48. Gstaiger, M., Georgiev, O., Van Leeuwen, H., Van Der Vliet, P. Schaffner, W. (1996). The B cell coactivator Bob1 shows DNA sequence-dependent complex formation with Oct-1/Oct-2 factors, leading to differential promoter activation. EMBO J. 15, 2781 2790.
49. Guo, Y., Einhorn, L., Kelley, M., Hirota, K., Yodoi, J., Reinbold, R., Scholer, H., Ramsey, H. Hromas, R. (2004). Redox regulation of the embryonic stem cell transcription factor oct-4 by thioredoxin. Stem Cells 22, 259 264.
50. Haass, N.K. Herlyn, M. (2005). Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J. Investig. Dermatol. Symp. Proc. 10, 153 163.
51. Hara, Y., Rovescalli, A.C., Kim, Y. Nirenberg, M. (1992). Structure and evolution of four POU domain genes expressed in mouse brain. Proc. Natl Acad. Sci. USA 89, 3280 3284.
52. Heckman, C.A., Duan, H., Garcia, P.B. Boxer, L.M. (2006). Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene 25, 888 898.
53. Herr, W. Cleary, M.A. (1995). The POU domain: versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. Genes Dev. 9, 1679 1693.
54. Herr, W., Sturm, R.A., Clerc, R.G. et al. (1988). The POU domain: a large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products. Genes Dev. 2, 1513 1516.
55. Hochedlinger, K., Yamada, Y., Beard, C. Jaenisch, R. (2005). Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465 477.
56. Hoefnagel, J.J., Dijkman, R., Basso, K., Jansen, P.M., Hallermann, C., Willemze, R., Tensen, C.P. Vermeer, M.H. (2005). Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105, 3671 3678.
57. Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert, N., Schaerer, L., Hemmi, S. Dummer, R. (2008). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650 656.
58. Huang, Y.T., Iwamoto, K., Kurosaki, T., Nasu, M. Ueda, S. (2005). The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases. Neurosci. Lett. 382, 175 178.
59. Irshad, S., Pedley, R.B., Anderson, J., Latchman, D.S. Budhram-Mahadeo, V. (2004). The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo. J. Biol. Chem. 279, 21617 21627.
60. Ivan, D., Diwan, A.H., Esteva, F.J. Prieto, V.G. (2004). Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod. Pathol. 17, 811 818.
61. Jaegle, M., Ghazvini, M., Mandemakers, W., Piirsoo, M., Driegen, S., Levavasseur, F., Raghoenath, S., Grosveld, F. Meijer, D. (2003). The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development. Genes Dev. 17, 1380 1391.
62. Jin, S., Fan, F., Fan, W., Zhao, H., Tong, T., Blanck, P., Alomo, I., Rajasekaran, B. Zhan, Q. (2001). Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene 20, 2683 2690.
63. Kapiloff, M.S., Farkash, Y., Wegner, M. Rosenfeld, M.G. (1991). Variable effects of phosphorylation of Pit-1 dictated by the DNA response elements. Science 253, 786 789.
64. Kasibhatla, S., Tailor, P., Bonefoy-Berard, N., Mustelin, T., Altman, A. Fotedar, A. (1999). Jun kinase phosphorylates and regulates the DNA binding activity of an octamer binding protein, T-cell factor beta1. Mol. Cell. Biol. 19, 2021 2031.
65. Klemm, J.D., Rould, M.A., Aurora, R., Herr, W. Pabo, C.O. (1994). Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell 77, 21 32.
66. Kuhlbrodt, K., Herbarth, B., Sock, E., Enderich, J., Hermans-Borgmeyer, I. Wegner, M. (1998a). Cooperative function of POU proteins and SOX proteins in glial cells. J. Biol. Chem. 273, 16050 16057.
67. Kuhlbrodt, K., Herbarth, B., Sock, E., Hermans-Borgmeyer, I. Wegner, M. (1998b). Sox10, a novel transcriptional modulator in glial cells. J. Neurosci. 18, 237 250.
68. Kuroda, T., Tada, M., Kubota, H., Kimura, H., Hatano, S.Y., Suemori, H., Nakatsuji, N. Tada, T. (2005). Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol. Cell. Biol. 25, 2475 2485.
69. Lang, D., Lu, M.M., Huang, L., Engleka, K.A., Zhang, M., Chu, E.Y., Lipner, S., Skoultchi, A., Millar, S.E. Epstein, J.A. (2005). Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433, 884 887.
70. Larue, L., Denat, L., Champeval, D., Goodall, J., Steunou, A., Bourgeois, Y., Nieto, L. Goding, C.R. (2007). T361 and S362 residues are modulating the proliferation potential of Brn2 in melanocytes. Pigment Cell Res. 20, 526.
71. Latchman, D.S. (1999). Regulation of DNA virus transcription by cellular POU family transcription factors. Rev. Med. Virol. 9, 31 38.
72. Lee, S.A., Ndisang, D., Patel, C. et al. (2005). Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter. Cancer Res. 65, 3072 3080.
73. Lefort, K., Rouault, J.P., Tondereau, L., Magaud, J.P. Dore, J.F. (2001). The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells. Oncogene 20, 7375 7385.
74. Lengner, C.J., Camargo, F.D., Hochedlinger, K., Welstead, G.G., Zaidi, S., Gokhale, S., Scholer, H.R., Tomilin, A. Jaenisch, R. (2007). Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 1, 403 415.
75. Leonard, J.H., Cook, A.L., Van Gele, M., Boyle, G.M., Inglis, K.J., Speleman, F. Sturm, R.A. (2002). Proneural and proneuroendocrine transcription factor expression in cutaneous mechanoreceptor (Merkel) cells and Merkel cell carcinoma. Int. J. Cancer 101, 103 110.
76. Looijenga, L.H., Stoop, H., De Leeuw, H.P. et al. (2003). POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 63, 2244 2250.
77. Luo, Y. Roeder, R.G. (1995). Cloning, functional characterization, and mechanism of action of the B-cell-specific transcriptional coactivator OCA-B. Mol. Cell. Biol. 15, 4115 4124.
78. Maier, T., Mestel, D., Besch, R., Nagele, U., Sturm, R. Berking, C. (2006). Expression of BRN2, osteopontin and nestin in melanoma and nevi. New markers of tumor progression? Exp. Dermatol. 15, 241.
79. Malik, K.F., Kim, J., Hartman, A.L., Kim, P. Young, W.S., 3rd. (1996). Binding preferences of the POU domain protein Brain-4: implications for autoregulation. Brain Res. Mol. Brain Res. 38, 209 221.
80. Malin, S., Linderson, Y., Almqvist, J., Ernberg, I., Tallone, T. Pettersson, S. (2005). DNA-dependent conversion of Oct-1 and Oct-2 into transcriptional repressors by Groucho/TLE. Nucleic Acids Res. 33, 4618 4625.
81. Malvagia, S., Poggi, G.M., Pasquini, E., Donati, M.A., Pela, I., Morrone, A. Zammarchi, E. (2003). The de novo Q167K mutation in the POU1F1 gene leads to combined pituitary hormone deficiency in an Italian patient. Pediatr. Res. 54, 635 640.
82. McCormick, A., Brady, H., Theill, L.E. Karin, M. (1990). Regulation of the pituitary-specific homeobox gene GHF1 by cell-autonomous and environmental cues. Nature 345, 829 832.
83. McEvilly, R.J., De Diaz, M.O., Schonemann, M.D., Hooshmand, F. Rosenfeld, M.G. (2002). Transcriptional regulation of cortical neuron migration by POU domain factors. Science 295, 1528 1532.
84. Millevoi, S., Thion, L., Joseph, G., Vossen, C., Ghisolfi-Nieto, L. Erard, M. (2001). Atypical binding of the neuronal POU protein N-Oct3 to noncanonical DNA targets. Implications for heterodimerization with HNF-3 beta. Eur. J. Biochem. 268, 781 791.
85. Miyagi, S., Nishimoto, M., Saito, T., Ninomiya, M., Sawamoto, K., Okano, H., Muramatsu, M., Oguro, H., Iwama, A. Okuda, A. (2006). The Sox2 regulatory region 2 functions as a neural stem cell-specific enhancer in the telencephalon. J. Biol. Chem. 281, 13374 13381.
86. Miyata, I., Vallette-Kasic, S., Saveanu, A. et al. (2006). Identification and functional analysis of the novel S179R POU1F1 mutation associated with combined pituitary hormone deficiency. J. Clin. Endocrinol. Metab. 91, 4981 4987.
87. Mollaaghababa, R. Pavan, W.J. (2003). The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene 22, 3024 3034.
88. Nakai, S., Kawano, H., Yudate, T. et al. (1995). The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev. 9, 3109 3121.
89. Nakshatri, H., Nakshatri, P. Currie, R.A. (1995). Interaction of Oct-1 with TFIIB. Implications for a novel response elicited through the proximal octamer site of the lipoprotein lipase promoter. J. Biol. Chem. 270, 19613 19623.
90. Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Scholer, H. Smith, A. (1998). Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379 391.
91. Nieto, L., Joseph, G., Stella, A., Henri, P., Burlet-Schiltz, O., Monsarrat, B., Clottes, E. Erard, M. (2007). Differential effects of phosphorylation on DNA binding properties of N Oct-3 are dictated by protein/DNA complex structures. J. Mol. Biol. 370, 687 700.
92. Nishimoto, M., Fukushima, A., Okuda, A. Muramatsu, M. (1999). The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. Mol. Cell. Biol. 19, 5453 5465.
93. Niwa, H., Miyazaki, J. Smith, A.G. (2000). Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 24, 372 376.
94. Okumura-Nakanishi, S., Saito, M., Niwa, H. Ishikawa, F. (2005). Oct-3/4 and Sox2 regulate Oct-3/4 gene in embryonic stem cells. J. Biol. Chem. 280, 5307 5317.
95. Pan, L., Yang, Z., Feng, L. Gan, L. (2005). Functional equivalence of Brn3 POU-domain transcription factors in mouse retinal neurogenesis. Development 132, 703 712.
96. Passeron, T., Valencia, J.C., Bertolotto, C., Hoashi, T., Le Pape, E., Takahashi, K., Ballotti, R. Hearing, V.J. (2007). SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation. Proc. Natl Acad. Sci. USA 104, 13984 13989.
97. Peixoto, P., Liu, Y., Depauw, S., Hildebrand, M.P., Boykin, D.W., Bailly, C., Wilson, W.D. David-Cordonnier, M.H. (2008). Direct inhibition of the DNA-binding activity of POU transcription factors Pit-1 and Brn-3 by selective binding of a phenyl-furan-benzimidazole dication. Nucleic Acids Res. 36, 3341 3353.
98. Perotti, D., De Vecchi, G., Testi, M.A. et al. (2004). Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. Hum. Mutat. 24, 400 407.
99. Pevzner, V., Kraft, R., Kostka, S. Lipp, M. (2000). Phosphorylation of Oct-2 at sites located in the POU domain induces differential down-regulation of Oct-2 DNA-binding ability. Biochem. J. 347, 29 35.
100. Pingault, V., Bondurand, N., Kuhlbrodt, K. et al. (1998). SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat. Genet. 18, 171 173.
101. Potterf, S.B., Furumura, M., Dunn, K.J., Arnheiter, H. Pavan, W.J. (2000). Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. Hum. Genet. 107, 1 6.
102. Qin, X.F., Luo, Y., Suh, H., Wayne, J., Misulovin, Z., Roeder, R.G. Nussenzweig, M.C. (1994). Transformation by homeobox genes can be mediated by selective transcriptional repression. EMBO J. 13, 5967 5976.
103. Qin, Y., Kong, L.K., Poirier, C., Truong, C., Overbeek, P.A. Bishop, C.E. (2004). Long-range activation of Sox9 in Odd Sex (Ods) mice. Hum. Mol. Genet. 13, 1213 1218.
104. Remenyi, A., Lins, K., Nissen, L.J., Reinbold, R., Scholer, H.R. Wilmanns, M. (2003). Crystal structure of a POU/HMG/DNA ternary complex suggests differential assembly of Oct4 and Sox2 on two enhancers. Genes Dev. 17, 2048 2059.
105. Remenyi, A., Scholer, H.R. Wilmanns, M. (2004). Combinatorial control of gene expression. Nat. Struct. Mol. Biol. 11, 812 815.
106. Renner, K., Leger, H. Wegner, M. (1994). The POU domain protein Tst-1 and papovaviral large tumor antigen function synergistically to stimulate glia-specific gene expression of JC virus. Proc. Natl Acad. Sci. USA 91, 6433 6437.
107. Rhee, J.M., Gruber, C.A., Brodie, T.B., Trieu, M. Turner, E.E. (1998). Highly cooperative homodimerization is a conserved property of neural POU proteins. J. Biol. Chem. 273, 34196 34205.
108. Rigoni, P., Xu, L., Harshman, K., Schaffner, W. Arnosti, D.N. (1993). Conserved cysteine residues of Oct-2 POU domain confer sensitivity to oxidation but are dispensable for sequence-specific DNA binding. Biochim. Biophys. Acta 1173, 141 146.
109. Rimm, D.L., Caca, K., Hu, G., Harrison, F.B. Fearon, E.R. (1999). Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154, 325 329.
110. Rodda, D.J., Chew, J.L., Lim, L.H., Loh, Y.H., Wang, B., Ng, H.H. Robson, P. (2005). Transcriptional regulation of nanog by OCT4 and SOX2. J. Biol. Chem. 280, 24731 24737.
111. Ryan, A.K. Rosenfeld, M.G. (1997). POU domain family values: flexibility, partnerships, and developmental codes. Genes Dev. 11, 1207 1225.
112. Satyamoorthy, K., Li, G., Gerrero, M.R., Brose, M.S., Volpe, P., Weber, B.L., Van Belle, P., Elder, D.E. Herlyn, M. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63, 756 759.
113. Schatton, T. Frank, M.H. (2008). Cancer sem cells and human malignant melanoma. Pigment Cell Melanoma Res. 21, 39 55.
114. Schatton, T., Murphy, G.F., Frank, N.Y. et al. (2008). Identification of cells initiating human melanomas. Nature 451, 345 349.
115. Schonemann, M.D., Ryan, A.K., Mcevilly, R.J., O'connell, S.M., Arias, C.A., Kalla, K.A., Li, P., Sawchenko, P.E. Rosenfeld, M.G. (1995). Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev. 9, 3122 3135.
116. Schreiber, E., Harshman, K., Kemler, I., Malipiero, U., Schaffner, W. Fontana, A. (1990). Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. Nucleic Acids Res. 18, 5495 5503.
117. Schreiber, E., Tobler, A., Malipiero, U., Schaffner, W. Fontana, A. (1993). cDNA cloning of human N-Oct3, a nervous-system specific POU domain transcription factor binding to the octamer DNA motif. Nucleic Acids Res. 21, 253 258.
118. Schreiber, J., Enderich, J., Sock, E., Schmidt, C., Richter-Landsberg, C. Wegner, M. (1997). Redundancy of class III POU proteins in the oligodendrocyte lineage. J. Biol. Chem. 272, 32286 32293.
119. Scully, K.M. Rosenfeld, M.G. (2002). Pituitary development: regulatory codes in mammalian organogenesis. Science 295, 2231 2235.
120. Scully, K.M., Jacobson, E.M., Jepsen, K., Lunyak, V., Viadiu, H., Carriere, C., Rose, D.W., Hooshmand, F., Aggarwal, A.K. Rosenfeld, M.G. (2000). Allosteric effects of Pit-1 DNA sites on long-term repression in cell type specification. Science 290, 1127 1131.
121. Smit, D.J., Smith, A.G., Parsons, P.G., Muscat, G.E. Sturm, R.A. (2000). Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors. Eur. J. Biochem. 267, 6413 6422.
122. Smith, A.G., Brightwell, G., Smit, S.E., Parsons, P.G. Sturm, R.A. (1998). Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction. Melanoma Res. 8, 2 10.
123. Southard-Smith, E.M., Kos, L. Pavan, W.J. (1998). Sox10 mutation disrupts neural crest development in Dom Hirschsprung mouse model. Nat. Genet. 18, 60 64.
124. Stolt, C.C., Lommes, P., Hillgartner, S. Wegner, M. 2008 The transcription factor Sox5 modulates Sox10 function during melanocyte development. Nucleic Acids Res. 36, 5427 5440.
125. Sturm, R.A. Herr, W. (1988). The POU domain is a bipartite DNA-binding structure. Nature 336, 601 604.
126. Sturm, R.A., Bisshop, F., Takahashi, H. Parsons, P.G. (1991). A melanoma octamer binding protein is responsive to differentiating agents. Cell Growth Differ. 2, 519 524.
127. Sturm, R.A., O'Sullivan, B.J., Thomson, J.A., Jamshidi, N., Pedley, J. Parsons, P.G. (1994). Expression studies of pigmentation and POU-domain genes in human melanoma cells. Pigment Cell Res. 7, 235 240.
128. Sugihara, T.M., Kudryavtseva, E.I., Kumar, V., Horridge, J.J. Andersen, B. (2001). The POU domain factor Skin-1a represses the keratin 14 promoter independent of DNA binding. A possible role for interactions between Skn-1a and CREB-binding protein/p300. J. Biol. Chem. 276, 33036 33044.
129. Sugitani, Y., Nakai, S., Minowa, O., Nishi, M., Jishage, K., Kawano, H., Mori, K., Ogawa, M. Noda, T. (2002). Brn-1 and Brn-2 share crucial roles in the production and positioning of mouse neocortical neurons. Genes Dev. 16, 1760 1765.
130. Sunabori, T., Tokunaga, A., Nagai, T., Sawamoto, K., Okabe, M., Miyawaki, A., Matsuzaki, Y., Miyata, T. Okano, H. (2008). Cell-cycle-specific nestin expression coordinates with morphological changes in embryonic cortical neural progenitors. J. Cell Sci. 121, 1204 1212.
131. Tachibana, M., Kobayashi, Y. Matsushima, Y. (2003). Mouse models for four types of Waardenburg syndrome. Pigment Cell Res. 16, 448 454.
132. Tai, M.H., Chang, C.C., Kiupel, M., Webster, J.D., Olson, L.K. Trosko, J.E. (2005). Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26, 495 502.
133. Takahashi, K. Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663 676.
134. Takahashi, S., Saito, S., Ohtani, N. Sakai, T. (2001). Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res. 61, 1187 1195.
135. Tanaka, S., Kamachi, Y., Tanouchi, A., Hamada, H., Jing, N. Kondoh, H. (2004). Interplay of SOX and POU factors in regulation of the Nestin gene in neural primordial cells. Mol. Cell. Biol. 24, 8834 8846.
136. Thomson, J.A., Parsons, P.G. Sturm, R.A. (1993). In vivo and in vitro expression of octamer binding proteins in human melanoma metastases, brain tissue, and fibroblasts. Pigment Cell Res. 6, 13 22.
137. Thomson, J.A.F., Murphy, K., Baker, E., Sutherland, G.R., Parsons, P.G. Sturm, R.A. (1995). The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 11, 691 700.
138. Tokuzawa, Y., Kaiho, E., Maruyama, M., Takahashi, K., Mitsui, K., Maeda, M., Niwa, H. Yamanaka, S. (2003). Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol. Cell. Biol. 23, 2699 2708.
139. Tomilin, A., Remenyi, A., Lins, K., Bak, H., Leidel, S., Vriend, G., Wilmanns, M. Scholer, H.R. (2000). Synergism with the coactivator OBF-1 (OCA-B, BOB-1) is mediated by a specific POU dimer configuration. Cell 103, 853 864.
140. Tomioka, M., Nishimoto, M., Miyagi, S., Katayanagi, T., Fukui, N., Niwa, H., Muramatsu, M. Okuda, A. (2002). Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. Nucleic Acids Res. 30, 3202 3213.
141. Tomoda, K., Kubota, Y. Kato, J. (1999). Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398, 160 165.
142. Tonks, I.D., Hacker, E., Irwin, N. et al. (2005). Melanocytes in conditional Rb-/- mice are normal in vivo but exhibit proliferation and pigmentation defects in vitro. Pigment Cell Res. 18, 252 264.
143. Tonks, I.D., Hayward, N.K. Kay, G.F. (2006). Pocket protein function in melanocyte homeostasis and neoplasia. Pigment Cell Res. 19, 260 283.
144. Topilko, P., Schneider-Maunoury, S., Levi, G., Baron-Van Evercooren, A., Chennoufi, A.B., Seitanidou, T., Babinet, C. Charnay, P. (1994). Krox-20 controls myelination in the peripheral nervous system. Nature 371, 796 799.
145. Trieu, M., Ma, A., Eng, S.R., Fedtsova, N. Turner, E.E. (2003). Direct autoregulation and gene dosage compensation by POU-domain transcription factor Brn3a. Development 130, 111 121.
146. Vahava, O., Morell, R., Lynch, E.D. et al. (1998). Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans. Science 279, 1950 1954.
147. Vallette-Kasic, S., Pellegrini-Bouiller, I., Sampieri, F., Gunz, G., Diaz, A., Radovick, S., Enjalbert, A. Brue, T. (2001). Combined pituitary hormone deficiency due to the F135C human Pit-1 (pituitary-specific factor 1) gene mutation: functional and structural correlates. Mol. Endocrinol. 15, 411 420.
148. Van Leeuwen, H.C., Strating, M.J., Cox, M., Kaptein, R. Van Der Vliet, P.C. (1995). Mutation of the Oct-1 POU-specific recognition helix leads to altered DNA binding and influences enhancement of adenovirus DNA replication. Nucleic Acids Res. 23, 3189 3197.
149. Vance, K.W. Goding, C.R. (2004). The transcription network regulating melanocyte development and melanoma. Pigment Cell Res. 17, 318 325.
150. Waragai, M., Lammers, C.H., Takeuchi, S., Imafuku, I., Udagawa, Y., Kanazawa, I., Kawabata, M., Mouradian, M.M. Okazawa, H. (1999). PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Hum. Mol. Genet. 8, 977 987.
151. Wegner, M. (2005). Secrets to a healthy Sox life: lessons for melanocytes. Pigment Cell Res. 18, 74 85.
152. Wegner, M., Drolet, D.W. Rosenfeld, M.G. (1993). POU-domain proteins: structure and function of developmental regulators. Curr. Opin. Cell Biol. 5, 488 498.
153. Wei, F., Scholer, H.R. Atchison, M.L. (2007). Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J. Biol. Chem. 282, 21551 21560.
154. Wellbrock, C. Marais, R. (2005). Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170, 703 708.
155. Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T. Marais, R. (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3, e2734.
156. Wysocka, J. Herr, W. (2003). The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem. Sci. 28, 294 304.
157. Xu, L., Lavinsky, R.M., Dasen, J.S. et al. (1998). Signal-specific co-activator domain requirements for Pit-1 activation. Nature 395, 301 306.
158. Xu, H.M., Liao, B., Zhang, Q.J., Wang, B.B., Li, H., Zhong, X.M., Sheng, H.Z., Zhao, Y.X., Zhao, Y.M. Jin, Y. (2004). Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J. Biol. Chem. 279, 23495 23503.
159. Yamaguchi, S., Yamazaki, Y., Ishikawa, Y., Kawaguchi, N., Mukai, H. Nakamura, T. (2005). EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 43, 217 222.
160. Yuan, H., Corbi, N., Basilico, C. Dailey, L. (1995). Developmental- specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev. 9, 2635 2645.
161. Zhang, Z., Huettner, P.C., Nguyen, L., Bidder, M., Funk, M.C., Li, J. Rader, J.S. (2006). Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 25, 5436 5445.
162. Zhang, Z., Liao, B., Xu, M. Jin, Y. (2007). Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1. FASEB J. 21, 3042 3051.
163. Zwilling, S., Annweiler, A. Wirth, T. (1994). The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP. Nucleic Acids Res. 22, 1655 1662.